Severe respiratory failure and sepsis – Bench to bedside and future research directions

2pm – 3.15pm BST, 2 July 2025 ‐ 1 hour 15 mins

Stream 1

Outline of proposed content:

This session will explore the heterogeneity in pneumonia, ARDS and sepsis and evaluate the potential benefits of precision medicine to improve patient outcomes and how this can be enabled.

The role of corticosteroids in severe pneumonia will be reviewed, questioning whether their use should be extended to other indications.

Finally research priorities for effective therapies for sepsis patients will be reviewed.

Learning objectives

  1. Recognise the diverse lung phenotypes in pneumonia and ARDS.
  2. Evaluate the potential benefits of precision medicine to inform targeted treatment strategies and improve patient outcomes
  3. Analysis of the current evidence on steroid efficacy and safety, as well as considerations for patient selection and timing of administration.
  4. Understand the potential impact of the PANTHER platform trial in ARDS.
  5. Identify the current priorities in sepsis diagnosis and management.

 

Andrew Conway Morris - Identifying lung phenotypes in pneumonia and ARDS – time for personalised medicine 

Manu Shankar-Hari - Steroids for severe pneumonia -just for CAP or beyond?

Danny McAuley - Towards precision medicine in ARDS

Bronwen Connolly - Sepsis JLA priority setting exercise